

## **Pharmacy Drug Policy Checklist**

POLICY NAME Preventive Vaccine Policy POLICY # 3132P

## Criteria

The following vaccines are covered with zero member cost share.	
	Acthib—Haemophilus B conjugate  • Max age: 6 years
	Adacel—tetanus toxin-diphtheria-acellular pertussis
	Afluria—influenza quadrivalent
	Bexsero—meningococcal B
	Beyfortus – respiratory syncytial virus  • Max age: 24 months
	Boostrix— tetanus toxin-diphtheria-acellular pertussis
	Capvaxive – pneumococcal 21-valent conjugate
	Covid-19—covid-19 (SARS-COV-2) vaccine  • Max dose: 3 per 365 days  • Age limits based on product package label
	Daptacel — tetanus toxin-diphtheria-acellular pertussis
	Dengvaxia – dengue (coverage under the Preventive benefit requires prior authorization)  • Minimum age: 9 years  • Maxium age: 16 years  • Documentation of a laboratory-confirmed previous Dengue viral infection and patient lives in an area where Dengue is endemic.
	Engerix-B—hepatitis B
	FLuad –influenza type A&B surface ant adj quad • Min age: 65 years
	Fluarix— influenza quadrivalent
	Flublok— influenza quadrivalent
	Flucelvax— influenza quadrivalent
	Flulaval— influenza quadrivalent

Flumist—influenza live attenuated  • Min age: 2 years
• Max age: 49 years
Fluzone HD—influenza high-dose  • Min age: 65 years Policy & Procedure
Fluzone Quad— influenza quadrivalent
Gardasil 9—human papillomavirus (HPV)  • Min age: 9 years
• Max age: 27 years
Havrix—hepatitis A
Heplisav-B—hepatitis B • Min age: 18 years
Hiberix—Haemophilus B • Max age: 6 years
Infanrix—diphtheria-acellular pertussis-poliovirus
Ipol—poliovirus, IPV • Max age: 17 years
Kinrix—diph-tet-acell pert-polio-IPV
Menquadi meningococcal (A, C, Y, and W-135) Tetanus
Menveo meningococcal (A, C, Y, and W-135) Oligo
MMR II—measles-mumps-rubella
Novavax—covid-19 (SARS-COV-2) mRNA
Pediarix—diph-tetanus tox-acell pert-hepatitis B- polio IPV
Pedvax HIB—Haemophilus B Polysaccharide • Max age: 6 years
Penbraya—meningococcal (A, B, C, W, and Y)  • Max age: 25 years
Pentacel—diph-tetanus tox-Acell pert-hepatitis B-Polio IPV
Pneumovax 23—pneumococcal polyvalent
Prevnar 20—pneumococcal 20-valent conjugate
Proquad – measles-mumps-rubella-varicella
Quadracel—diph-tetanus tox ad-acell pert & polio, IPV

Recombivax HB—hepatitis B (Recombinant)
Respiratory Syncytial Virus (RSV)  • Including (but not limited to): Arexvy, Abrysvo, mResvia  • Min age: 60 years old ② Abrysvo only: pregnant patients 32-36 weeks' gestation
Rotarix—rotavirus, live for oral suspension • Max age: 8 years
Rotateq—rotavirus, live oral  • Max age: 8 years
Shingrix—zoster recombinant adjuvanted for IM  • Max: 2 per lifetime  • Min age: 50 years  • Ages 19 to 49 who are immunocompromised: Requires Prior Authorization Approval for this age group requires that member is immunodeficient or immunocompromised because of disease or therapy: ? Hematopoietic cell transplant recipients ? Patients with hematologic malignancies ? Renal or other solid organ transplant recipients ? Patients with solid tumor malignancies ? Persons living with HIV ? Patients with primary immunodeficiencies ? Patients with autoimmune and inflammatory conditions ? Patients taking immunosuppressive medications or therapies
TDVax—tetanus-diphtheria toxoids
Tenivac—tetanus-diphtheria toxoids
Tet/Dip tox tetanus-diphtheria toxoids
Trumenba—meningococcal group B
Twinrix—hep A-hep B
Vaqta—hepatitis A
Varivax—varicella live for SC
Vaxelis—diph-tet tox-acell pert AD-polio IPV-HIB-Hep B
Vaxneuvance—pneumococcal 15-valent conjugate Created Date: 04/06/22 Effective Date: 04/06/22 Posted to Website: 04/06/22 Revision Date: 08/07/24 DISCLAIMER This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web.